|
Hoffmann-La Roche is the US prescription pharmaceuticals unit of Roche. The company develops, manufactures, and markets drugs to treat such life-threatening conditions as AIDS, cancer, and heart disease. Other product categories include central nervous system (CNS) disorders, organ transplant rejection, and skin conditions. Hoffmann-La Roche's products include influenza fighter Tamiflu, cancer drug Xeloda, HIV inhibitor Fuzeon (co-marketed with Trimeris), obesity drug Xenical, and hepatitis B and C therapy Pegasys. Hoffmann-La Roche's R&D is focused on oncology and metabolic, CNS, virology, inflammatory, respiratory, and autoimmune diseases.
|
| | | Contact Information | |
Address: |
340 Kingsland St.
Nutley, NJ 07110-1199
| | Phone: | 973-235-5000 | | Fax: | 973-777-3327 |
|
| Financial
Highlights | | Fiscal Year End: | December |
|
|
Key People
| | • |
President and CEO:
George B. Abercrombie
| | • |
VP Finance and Information Technology:
Ivor MacLeod
| | • |
Director Public Affairs:
Virginia A. (Ginny) Valenze
|
|
|
